Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 12/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.35 |
| ▸ | FLT3 | P36888 | 4/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951830 | 0.84 | TNK2 (0.36) | TNK2KDRFLT3LCKBTK | |
| SCHEMBL2959345 | 0.78 | TNK2 (0.46) | TNK2SRCWEE1 | |
| SCHEMBL2949287 | 0.74 | CDC7 (0.40) | TNK2KDRFLT3SRC | |
| SCHEMBL2949395 | 0.70 | TNK2 (0.60) | TNK2KDRLCKBTKJAK3 | |
| SCHEMBL2955963 | 0.67 | TNK2 (0.70) | TNK2KDRLCKBTKJAK3 | |
| SCHEMBL30338434 | 0.67 | TNK2 (0.55) | TNK2KDRLCKBTKJAK3 | |
| SCHEMBL2952193 | 0.64 | TNK2 (0.64) | TNK2KDRLCKBTKJAK3 | |
| SCHEMBL21960889 | 0.60 | HTR2C (0.35) | TNK2GAA | |
| SCHEMBL21960894 | 0.60 | POLB (0.46) | TNK2GAA | |
| SCHEMBL30338409 | 0.59 | TNK2 (0.84) | TNK2KDRLCKBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885KDR 1313/4885FLT3 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.